Skye Bioscience, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a pending transaction with Redx, the planned termination of its CBeyond clinical trial, a material weakness in internal controls, and going concern risk.

Key Highlights

  • Share count: As of November 10, 2026, there were 4,423,469 shares of common stock, $0.001 par value, issued and outstanding.
  • Pending transaction: The company disclosed a pending transaction with Redx, referred to throughout the filing as "the Transaction."
  • CBeyond trial: The filing references the expected termination of the company's Phase 2a CBeyond clinical trial.
  • Pipeline asset: Future clinical trials of nimacimab are described as dependent on the company's capital resources.
  • Material weakness: The company disclosed a material weakness in its internal control over financial reporting.
  • Going concern: The filing identifies the company's ability to continue as a going concern as a key risk and forward-looking uncertainty.
  • Exchange listing: Common stock is listed on NASDAQ:SKYE.

Skye Bioscience Discloses Redx Transaction Terms and Clinical Trial Developments

According to the filing, Skye Bioscience, Inc., a Nevada-incorporated clinical-stage bioscience company headquartered at 11250 El Camino Real, Suite 100, San Diego, CA 92130, submitted its Form 10-Q for the quarterly period ended September 30, 2026 as a smaller reporting company and non-accelerated filer. The company's common stock, with a par value of $0.001 per share, is registered on the Nasdaq Stock Exchange LLC under the trading symbol SKYE.

The filing discloses a pending acquisition transaction with Redx, identified throughout the document as "the Transaction." The company lists multiple risks associated with the pending deal, including the possibility that required shareholder approvals or regulatory approvals may not be obtained, that closing conditions may not be satisfied or waived, and that the expected benefits from the Transaction "will not be realized or will not be realized within the expected time period." The filing also notes that Redx and the company "will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected," according to its cautionary language.

Separately, the company disclosed its expectation of terminating its Phase 2a CBeyond clinical trial. The filing identifies nimacimab as a pipeline asset, stating that "the initiation and design of any future clinical trials of nimacimab will be impacted by the Company's capital resources." The company also disclosed a material weakness in internal control over financial reporting and cited its ability to raise capital and "to continue as a going concern" as a forward-looking uncertainty subject to material risks. These disclosures are the company's own characterizations and are subject to the cautionary language contained in the filing.

What Was Disclosed

This Form 10-Q covers the quarterly period ended September 30, 2026 for Skye Bioscience, Inc. (NASDAQ:SKYE). The filing reports 4,423,469 shares outstanding as of November 10, 2026, and discloses a pending transaction with Redx, the planned termination of the CBeyond Phase 2a trial, a material weakness in internal controls, and going concern risk tied to the company's capital position.

The company also identified risks associated with intellectual property protection, potential legal proceedings, and the effect of the pending Transaction on employee retention, stock price, and ongoing operations. All forward-looking statements in the filing are the company's own and are subject to its cautionary language as described in the document.